ISIS PHARMACEUTICALS INC ANTISENSE THERAPEUTICS LTD STOCK PURCHASE AGREEMENTStock Purchase Agreement • January 4th, 2002 • Isis Pharmaceuticals Inc • Pharmaceutical preparations • Victoria
TEXT OMITTED AND FILED SEPARATELY "CONFIDENTIAL TREATMENT REQUESTED UNDER 17 C.F.R. SECTIONS 200.80(B)(4), 200.83 AND 240.24b-2." SECURITIES PURCHASE AGREEMENT SECURITIES PURCHASE AGREEMENT (this "Agreement"), dated as of January 14, 2000, between...Securities Purchase Agreement • January 28th, 2000 • Isis Pharmaceuticals Inc • Pharmaceutical preparations • Delaware
Common StockUnderwriting Agreement • October 22nd, 2001 • Isis Pharmaceuticals Inc • Pharmaceutical preparations • New York
BETWEENLicense Agreement • January 28th, 2000 • Isis Pharmaceuticals Inc • Pharmaceutical preparations • New York
EXHIBIT 99.3 FORM OF RIGHT CERTIFICATE (EXHIBIT B TO RIGHTS AGREEMENT)Rights Agreement • December 13th, 2000 • Isis Pharmaceuticals Inc • Pharmaceutical preparations
ARTICLE II REPRESENTATIONS AND WARRANTIES OF THE COMPANYSecurities Purchase Agreement • August 29th, 2001 • Isis Pharmaceuticals Inc • Pharmaceutical preparations • Delaware
1 EXHIBIT 10.5 ISIS PHARMACEUTICALS, INC. REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (the "Agreement") is made as of January 14, 2000 by and between ISIS PHARMACEUTICALS, INC., a Delaware corporation (the "Company"), and ELAN...Registration Rights Agreement • January 28th, 2000 • Isis Pharmaceuticals Inc • Pharmaceutical preparations • Delaware
IONIS PHARMACEUTICALS, INC. AND U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, as Trustee INDENTURE Dated as of June 12, 2023 1.75% Convertible Senior Notes due 2028Indenture • June 12th, 2023 • Ionis Pharmaceuticals Inc • Pharmaceutical preparations • New York
INDENTURE dated as of June 12, 2023 between IONIS PHARMACEUTICALS, INC., a Delaware corporation, as issuer (the “Company,” as more fully set forth in Section 1.01) and U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, a national banking association, as trustee (the “Trustee,” as more fully set forth in Section 1.01).
MASTER AGREEMENT This Master Agreement is entered into and made effective as of October 30, 2001 (the "Effective Date"), between ISIS PHARMACEUTICALS, INC. of 2292 Faraday Avenue, Carlsbad, CA 92008, USA ("ISIS") and ANTISENSE THERAPEUTICS LTD., ACN...Master Agreement • January 4th, 2002 • Isis Pharmaceuticals Inc • Pharmaceutical preparations
1 EXHIBIT 10.4 THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND MAY NOT UNDER ANY CIRCUMSTANCES BE SOLD, TRANSFERRED OR OTHERWISE DISPOSED OF WITHOUT...Warrant Agreement • May 3rd, 1999 • Isis Pharmaceuticals Inc • Pharmaceutical preparations • Delaware
By and betweenLicensing Agreement • January 4th, 2002 • Isis Pharmaceuticals Inc • Pharmaceutical preparations • New York
BY AND BETWEEN ORASENSE LTDLicense Agreement • June 16th, 1999 • Isis Pharmaceuticals Inc • Pharmaceutical preparations • New York
1 EXHIBIT 10.2Confidentiality Agreement • August 12th, 1997 • Isis Pharmaceuticals Inc • Pharmaceutical preparations • New York
ANDRights Agreement • December 13th, 2000 • Isis Pharmaceuticals Inc • Pharmaceutical preparations • Delaware
Exhibit 2.4 *Text Omitted and Filed Separately Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) 200.83 and 240.24b-2 COLLABORATION AGREEMENT BETWEEN ELI LILLY AND COMPANY AND ISIS PHARMACEUTICALS, INC. AUGUST 17, 2001Collaboration Agreement • August 29th, 2001 • Isis Pharmaceuticals Inc • Pharmaceutical preparations • New York
ORASENSE LTDLicense Agreement • June 16th, 1999 • Isis Pharmaceuticals Inc • Pharmaceutical preparations • New York
1 EXHIBIT 10.6 HEPASENSE LTD. REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (the "Agreement") is made as of January 14, 2000, by and among HEPASENSE LTD., a Bermuda exempted limited liability company (the "Company"), ISIS...Registration Rights Agreement • January 28th, 2000 • Isis Pharmaceuticals Inc • Pharmaceutical preparations • New York
Text Omitted and Filed Separately Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) 200.83 and 240.24b-2 DEVELOPMENT AND LICENSE AGREEMENTDevelopment and License Agreement • October 11th, 2001 • Isis Pharmaceuticals Inc • Pharmaceutical preparations • New Jersey
ARTICLE IPurchase Agreement • August 14th, 1998 • Isis Pharmaceuticals Inc • Pharmaceutical preparations • New York
CONFIDENTIAL TREATMENT REQUESTED UNDER 17 C.F.R. SECTIONS 200.80(b)4 AND 240.24B-2 COLLABORATION AND LICENSE AGREEMENT This Collaboration and License Agreement (the "Agreement") between ISIS PHARMACEUTICALS, INC. of 2292 Faraday Avenue, Carlsbad, CA...Collaboration and License Agreement • January 4th, 2002 • Isis Pharmaceuticals Inc • Pharmaceutical preparations • Delaware
LOAN AGREEMENTLoan Agreement • July 21st, 2017 • Ionis Pharmaceuticals Inc • Pharmaceutical preparations • New York
THIS LOAN AGREEMENT, dated as of July 18, 2017 (as amended, restated, replaced, supplemented or otherwise modified from time to time, this “Agreement”), between UBS AG, by and through its branch office at 1285 Avenue of the Americas, New York, New York, having an address at 1285 Avenue of the Americas, 11th Floor, New York, New York 10019 (together with its successors and assigns, collectively, “Lender”), and IONIS FARADAY, LLC, a Delaware limited liability company having an address at 2855 Gazelle Court, Carlsbad, California 92010 (together with its permitted successors and assigns, collectively, “Borrower”).
AGREEMENT BETWEENResearch and Development • June 14th, 1999 • Isis Pharmaceuticals Inc • Pharmaceutical preparations • Delaware
BACKGROUNDResearch and Development Agreement • March 31st, 1999 • Isis Pharmaceuticals Inc • Pharmaceutical preparations • Delaware
TEXT OMITTED AND FILED SEPARATELY "CONFIDENTIAL TREATMENT REQUESTED UNDER 17 C.F.R. SECTIONS 200.80(B)(4) 200.83 AND 240.24B-2" [*] RESEARCH COLLABORATION AND LICENSE AGREEMENTResearch Collaboration and License Agreement • August 14th, 2000 • Isis Pharmaceuticals Inc • Pharmaceutical preparations • California
AMENDMENT NO. 2Amendment No. 2 • November 16th, 1998 • Isis Pharmaceuticals Inc • Pharmaceutical preparations
EXHIBIT 10.14Stock Option Agreement • March 28th, 2000 • Isis Pharmaceuticals Inc • Pharmaceutical preparations
COMMON STOCK PURCHASE AGREEMENT Dated May 30, 2006 by and between ISIS PHARMACEUTICALS, INC. and AZIMUTH OPPORTUNITY LTD.Common Stock Purchase Agreement • May 31st, 2006 • Isis Pharmaceuticals Inc • Pharmaceutical preparations • New York
This COMMON STOCK PURCHASE AGREEMENT, made and entered into on this 30th day of May 2006 (this “Agreement”), by and between Azimuth Opportunity Ltd., an international business company incorporated under the laws of the British Virgin Islands (the “Investor”), and Isis Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Company”).
LOAN AGREEMENTLoan Agreement • August 29th, 2001 • Isis Pharmaceuticals Inc • Pharmaceutical preparations • New York
TEXT OMITTED AND FILED SEPARATELY "CONFIDENTIAL TREATMENT REQUESTED UNDER 17 C.F.R. SECTIONS 200.80(B)(4), 200.83 AND 240.24B-2." SUBSCRIPTION, JOINT DEVELOPMENT AND OPERATING AGREEMENT ELAN CORPORATION, PLC (ACTING THROUGH ITS DIVISION ELAN...Subscription, Joint Development and Operating Agreement • January 28th, 2000 • Isis Pharmaceuticals Inc • Pharmaceutical preparations • New York
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • May 24th, 2002 • Isis Pharmaceuticals Inc • Pharmaceutical preparations • New York
THIS REGISTRATION RIGHTS AGREEMENT (the “Agreement”) is made and entered into as of May 1, 2002, by and between Isis Pharmaceuticals, Inc., a Delaware corporation (the “Company”) and UBS Warburg LLC and the other Initial Purchasers named in the Purchase Agreement referred to below (collectively, the “Initial Purchasers”), for whom UBS Warburg LLC is acting as representative, pursuant to that certain Purchase Agreement, dated as of April 26, 2002 (the “Purchase Agreement”) between the Company and the Initial Purchasers.
To: Ionis Pharmaceuticals, Inc. Carlsbad, CA 92010 Attention: General Counsel Email: legalnotices@ionisph.comCall Option Transaction • April 13th, 2021 • Ionis Pharmaceuticals Inc • Pharmaceutical preparations • New York
The purpose of this letter agreement (this “Confirmation”) is to confirm the terms and conditions of the call option transaction entered into between [_______] (“Dealer”) and Ionis Pharmaceuticals, Inc. (“Counterparty”) as of the Trade Date specified below (the “Transaction”). This letter agreement constitutes a “Confirmation” as referred to in the ISDA Master Agreement specified below. Each party further agrees that this Confirmation together with the Agreement evidence a complete binding agreement between Counterparty and Dealer as to the subject matter and terms of the Transaction to which this Confirmation relates, and shall supersede all prior or contemporaneous written or oral communications with respect thereto.
EXHIBIT 10.4 Optionee: STANLEY T. CROOKE Date: JANUARY 6, 2000 ----------------------------- ----------------------- ISIS PHARMACEUTICALS, INC. SUPPLEMENTAL STOCK OPTION AGREEMENT Isis Pharmaceuticals, Inc. (the "Company"), pursuant to its 1989 Stock...Supplemental Stock Option Agreement • February 28th, 2001 • Isis Pharmaceuticals Inc • Pharmaceutical preparations
1 EXHIBIT 10.4 Exhibit F to Securities Purchase Agreement THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND MAY NOT UNDER ANY CIRCUMSTANCES BE SOLD,...Securities Purchase Agreement • January 28th, 2000 • Isis Pharmaceuticals Inc • Pharmaceutical preparations • Delaware
PURCHASE AGREEMENTPurchase Agreement • January 24th, 2007 • Isis Pharmaceuticals Inc • Pharmaceutical preparations • New York
CONFIDENTIAL TREATMENT REQUESTED UNDER 17 C.F.R. Sections 200.80(b)4, AND 240.24b-2 COLLABORATION AGREEMENTCollaboration Agreement • January 4th, 2002 • Isis Pharmaceuticals Inc • Pharmaceutical preparations • California
